Early Screening for Developmental Language Disorder: Predictive Validity of German Parent Reports
Eveline Pinstock1, Satyam Antonio Schramm1
1Department of Inclusive Education, University of Potsdam, Germany.
International Journal of Language & Communication Disorders
|August 5, 2026
Summary
Parent questionnaires FRAKIS-K and SBE-2-KT adequately predict Developmental Language Disorder (DLD) risk in two-year-olds. Adjusting cut-offs may improve early detection, but further research is needed.
Area of Science:
- Child development research
- Clinical psychology
- Speech-language pathology
Background:
- Developmental Language Disorder (DLD) is a common condition with lasting impacts.
- Early identification is crucial, but predictive tools for DLD in German-speaking regions are limited.
- Existing parent-report tools like FRAKIS-K and SBE-2-KT lack systematic validation for DLD prediction.
Purpose of the Study:
- To assess the predictive validity of FRAKIS-K and SBE-2-KT at age two for identifying DLD risk at age four.
- To determine if adjusting screening cut-off values can enhance predictive accuracy.
Main Methods:
- A longitudinal study of 186 children assessed at age two and 145 at age four in Hanover, Germany.
- Children's expressive vocabulary and grammar were measured at age four using the P-ITPA.
- Predictive validity was evaluated using sensitivity, specificity, AUC, and RIOC; ROC analysis explored cut-off adjustments.
Main Results:
- The SBE-2-KT had moderate predictive power (AUC=0.85), and FRAKIS-K vocabulary alone performed similarly (AUC=0.83).
- Both tools showed adequate specificity but moderate sensitivity.
- Adjusting cut-offs improved sensitivity up to 71% with minimal loss in specificity.
Conclusions:
- FRAKIS-K (vocabulary) and SBE-2-KT are adequate first-tier screening tools for DLD risk at age two in the German U7 context.
- These tools effectively identify children not at risk, but positive screens require comprehensive assessment.
- Optimizing cut-offs may enhance early detection, though findings require validation in larger clinical samples.

